1,720,967 research outputs found
MSJ887343_supplemental_material – Supplemental material for Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling
No full textSupplemental material, MSJ887343_supplemental_material for Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling by Fabio Pellegrini, Massimiliano Copetti, Maria Pia Sormani, Francesca Bovis, Carl de Moor, Thomas PA Debray and Bernd C Kieseier in Multiple Sclerosis Journal</p
MSJ849513_supplementary_material – Supplemental material for A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis
No full textSupplemental material, MSJ849513_supplementary_material for A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis by Fabio Pellegrini, Massimiliano Copetti, Francesca Bovis, David Cheng, Robert Hyde, Carl de Moor, Bernd C Kieseier and Maria Pia Sormani in Multiple Sclerosis Journal</p
MSJ885613_supplemental_material – Supplemental material for Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
No full textSupplemental material, MSJ885613_supplemental_material for Neurofilament light levels are associated with long-term outcomes in multiple sclerosis by Jens Kuhle, Tatiana Plavina, Christian Barro, Giulio Disanto, Dipen Sangurdekar, Carol M Singh, Carl de Moor, Bob Engle, Bernd C Kieseier, Elizabeth Fisher, Ludwig Kappos, Richard A Rudick and Jaya Goyal in Multiple Sclerosis Journal</p
sj-docx-1-msj-10.1177_13524585211055934 – Supplemental material for Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study
No full textSupplemental material, sj-docx-1-msj-10.1177_13524585211055934 for Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study by Jun-ichi Kira, Jin Nakahara, Denis V Sazonov, Takayoshi Kurosawa, Isao Tsumiyama, Roman Willi, Martin Zalesak, Ratnakar Pingili, Dieter A Häring, Krishnan Ramanathan, Bernd C Kieseier, Martin Merschhemke, Wendy Su and Takahiko Saida in Multiple Sclerosis Journal</p
sj-docx-11-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-11-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-3-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-3-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-6-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-6-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-9-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-9-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-8-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-8-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-pdf-10-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-pdf-10-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
- …
